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Abstract
Background
Microorganisms in the human intestine (i.e. the gut microbiome) have an increasingly recog-
nized impact on human health, including brain functioning. Attention-deficit/hyperactivity dis-
order (ADHD) is a neurodevelopmental disorder associated with abnormalities in dopamine
neurotransmission and deficits in reward processing and its underlying neuro-circuitry
including the ventral striatum. The microbiome might contribute to ADHD etiology via the
gut-brain axis. In this pilot study, we investigated potential differences in the microbiome
between ADHD cases and undiagnosed controls, as well as its relation to neural reward
processing.
Methods
We used 16S rRNA marker gene sequencing (16S) to identify bacterial taxa and their pre-
dicted gene functions in 19 ADHD and 77 control participants. Using functional magnetic
resonance imaging (fMRI), we interrogated the effect of observed microbiome differences in
neural reward responses in a subset of 28 participants, independent of diagnosis.
Results
For the first time, we describe gut microbial makeup of adolescents and adults diagnosed
with ADHD. We found that the relative abundance of several bacterial taxa differed between
cases and controls, albeit marginally significant. A nominal increase in the Bifidobacterium
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genus was observed in ADHD cases. In a hypothesis-driven approach, we found that the
observed increase was linked to significantly enhanced 16S-based predicted bacterial gene
functionality encoding cyclohexadienyl dehydratase in cases relative to controls. This
enzyme is involved in the synthesis of phenylalanine, a precursor of dopamine. Increased
relative abundance of this functionality was significantly associated with decreased ventral
striatal fMRI responses during reward anticipation, independent of ADHD diagnosis and
age.
Conclusions
Our results show increases in gut microbiome predicted function of dopamine precursor
synthesis between ADHD cases and controls. This increase in microbiome function relates
to decreased neural responses to reward anticipation. Decreased neural reward anticipation
constitutes one of the hallmarks of ADHD.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder,
characterized by symptoms of inattention and/or impulsivity and hyperactivity. ADHD has
been associated with abnormalities in the monoamine neurotransmitter systems dopamine
and noradrenaline [1]. Stimulant medication, for example, is highly effective in improving
ADHD symptoms by inhibition of re-uptake of dopamine and noradrenaline by their trans-
porters [2]. Moreover, brain functions linked to dopamine processing, such as reward antici-
pation [3], have been found abnormal in ADHD, as reflected by diminished brain responses in
ventral striatum (including nucleus accumbens) in functional magnetic resonance imaging
(fMRI) studies [4–7]. ADHD is highly heritable [8, 9], and genetic studies have pointed to a
role of dopamine-, noradrenaline-, and serotonin-related genes in ADHD [8], but these stud-
ies showed small effects suggesting that environmental factors also play a role in the etiology of
ADHD.
Meta-analyses of non-pharmacologic treatment interventions for ADHD showed that
restriction diets for ADHD patients (usually directed at eliminating potential allergens) may
lead to a significant reduction in ADHD symptoms, although there is heterogeneity across
studies [10–12]. Conceivably, diet might influence behavior and ADHD symptoms by affect-
ing gut microorganisms (i.e. the gut microbiome) [13]. The gut microbiome has an increas-
ingly recognized impact on brain functioning and behavior [14]. One proposed mechanism
for the effects of gut microbiota on brain and behavior is through their ability to synthesize
neurochemicals and their precursors that are analogous in structure to those of the host ner-
vous system [15]. Precursors of monoamines involved in ADHD (i.e. dopamine, noradrena-
line, serotonin; see above) are produced by several members of the gut microbiota [16–18].
These precursors (i.e. phenylalanine, tyrosine, tryptophan) might be absorbed through the
intestinal epithelium, enter the portal circulation [15], and cross the blood-brain barrier; in
this way, they could potentially influence host monoamine synthesis (Fig 1). Consequently,
differences in abundance and/or metabolic activity of monoamine precursor-producing
inhabitants of the gastrointestinal tract may affect monoamine-related brain functioning and
behavior relevant to ADHD. Indeed, a lowered abundance of Bifidobacterium in infancy has
been associated with increased risk of developing ADHD and Asperger syndrome in child-
hood in a study focusing on particular microbiota [19]. However, we were not able to identify
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studies that investigated the (complete) gut microbiome in relation to ADHD, and how differ-
ences in microbiome structure might affect brain functioning.
Here, we present the first microbiome study in ADHD patients versus healthy controls. We
used bacterial 16S ribosomal RNA (rRNA) marker gene sequencing to characterize microbial
communities in adolescents and young adults with ADHD and self-reported healthy controls.
We specifically investigated the difference in relative abundance of monoamine precursor-
related predicted genes between these microbiomes, and their potential effect on brain activity.
We focused on the precursors in the monoamine biosynthesis, as monoamines themselves
cannot cross the blood-brain barrier [20], and indeed found overabundance of 16S-based pre-
dicted bacterial gene functionality related to phenylalanine synthesis in ADHD. Next, using
fMRI, we first replicated the finding of reduced reward anticipation in ventral striatum in
ADHD (see above) in a partly overlapping sample of the same cohort. Finally, in the subset of
participants with both microbiome and fMRI measurements, we assessed how microbiome
function related to neural responses during reward anticipation. We found that reduced
reward anticipation in ventral striatum was related to an increase in (predicted) bacterial func-
tionality with regard to production of dopamine’s precursor phenylalanine, independent of
diagnosis.
Methods
Participants
Microbiome sample. For the microbiome analyses, we included 96 participants, of whom
19 had been diagnosed with ADHD and 77 were healthy (Fig 2; Table 1; Text A in S1 Appen-
dix). ADHD cases were derived from the follow-up of the NeuroIMAGE study [22] (Neuro-
IMAGE II) and were diagnosed based on DSM-IV symptoms using the Schedule for Affective
Disorders and Schizophrenia for School-Age Children [23]. The sample of healthy individuals
was compiled of two sub-samples: (i) healthy participants (n = 17) and unaffected siblings of
ADHD probands (n = 21) of the ADHD cohort (NeuroIMAGE II project; not necessarily the
Fig 1. Potential routes in which precursors of monoamines could influence brain functioning. The
large neutral amino acids tryptophan, phenylalanine, and tyrosine, which are absorbed in the intestine [20],
are precursors of monoamines. Tryptophan and phenylalanine are essential amino acids, meaning that they
cannot be synthesized by the human body itself [21]. 5-HTP = 5-Hydroxytryptophan.
https://doi.org/10.1371/journal.pone.0183509.g001
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siblings of the cases in the current sample) and (ii) self-reported healthy volunteers (n = 39) of
the Brain Imaging Genetics (BIG) study [24].
fMRI sample. For the fMRI analyses, we included 87 participants from the above-men-
tioned ADHD cohort (NeuroIMAGE II project), of whom 24 had ADHD and 63 were unaf-
fected (Fig 2; Table 1; Text A in S1 Appendix). More participants were unaffected than
affected as this was a follow-up study and part of the children with ADHD no longer met the
diagnostic criteria in adolescence or adulthood of the current study. Of the 63 controls, 39 par-
ticipants were unaffected siblings of ADHD probands, and 24 participants were healthy
controls.
Out of initial 95 participants who underwent fMRI, eight participants were excluded from
analyses: one control due to significant drop-out in the back of the brain, two participants
(one ADHD and one control) due to less than 10 correct trials per cell in the factorial design,
five participants due to moving more than 5mm (translation; three ADHD and two controls).
For 28 included participants from the fMRI sample, group microbiome data was available:
6 patients with ADHD and 22 controls overlapped between both sample groups (Fig 2;
Table 1). Of the overlapping 22 controls, 13 participants were unaffected siblings, and 9 partic-
ipants were healthy controls. The regression analyses between the microbiome and the fMRI
measure in this sub-sample were performed across diagnosis (n = 28); see below.
The investigation was carried out in accordance with the latest version of the Declaration of
Helsinki. After complete description of the study to the participants, written informed consent
was obtained (and from their parents when <18 years old). The study was approved by the
regional medical ethics committee (Commissie Mensgebonden Onderzoek: CMO Regio Arn-
hem Nijmegen, number: NL41950.091.12).
fMRI analysis
Reward anticipation task. Reward anticipation was assessed during fMRI in the context
of a rewarded Stroop task (Fig A in S1 Appendix), adapted from a previous study [25], focus-
ing our analyses on reward cues (high > low reward cues). Neural responses to high versus
low reward cues in this task reflect motivation for monetary incentives, known to be depen-
dent on dopamine signaling in ventral striatum [3]. Using similar tasks, reward anticipation
responses were found to be reduced in patients with ADHD versus controls, and appear
negatively correlated with hyperactive-impulsive symptoms in ADHD [for a review, see 6].
Fig 2. Microbiome sample, fMRI sample, and their overlap.
https://doi.org/10.1371/journal.pone.0183509.g002
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MRI data acquisition, preprocessing, and analyses. Whole-brain functional images
(multi-echo) and a high-resolution anatomical scan were acquired on a 1.5T MR scanner
(Text B in S1 Appendix). All data were pre-processed and analyzed with SPM8 (http://www.
fil.ion.ucl.ac.uk/spm/). Echo combination, realignment, slice timing, co-registration, normali-
zation, and spatial smoothing are described in Text B in S1 Appendix.
For each participant, the resulting pre-processed fMRI time-series were analyzed at the first
level using an event-related approach in the context of a general linear model, including 24
motion parameters as regressors of non-interest (Text B in S1 Appendix). We performed
one-sample t-tests to assess the main effects of reward anticipation (high (15 ct)> low (1 ct)
reward cues) in the total sample (n = 87) as well as in the smaller sub-sample with microbiome
information (n = 28). To further account for motion, we added a summary motion score for
every subject in all second level analyses as covariate of non-interest (Text B in S1 Appendix).
Table 1. Descriptive characteristics of the study samples.
Microbiome Analysisa Imaging Analysisb Microbiome & Imaging Analysisc
ADHD
(n = 19)
Controls
(n = 77)
p ADHD
(n = 24)
Controls
(n = 63)
p ADHD
(n = 6)
Controls
(n = 22)
p
Age in Years (SD) 19.5 (2.5) 27.1 (14.3) .024 20.3 (3.7) 21.3 (3.4) n.s. 18.6 (2.5) 21.1 (3.3) n.s.
BMI (SD) 23.8 (4.1) 23.0 (3.2) n.s. 22.8 (3.5) 22.7 (2.9) n.s. 22.1 (4.4) 23.4 (3.7) n.s.
% Malesd 68.4 53.2 n.s. 75 61.9 n.s. 66.7 59.1 n.s.
Mean Inattention Symptoms
(SD)
6.5 (2.1) 0.7 (1.4)e < .001 6.2 (1.5) 0.5 (1.0) < .001 6.0 (1.6) 0.7 (1.3) < .001
Mean Hyperactivity
Symptoms (SD)
4.4 (2.1) 0.6 (1.1)e < .001 4.2 (2.4) 0.7 (1.2) < .001 5.0 (1.4) 0.7 (1.2) < .001
Mean Total Symptoms (SD) 11.0 (2.9) 1.3 (2.4)e < .001 10.3 (3.0) 1.2 (2.1) < .001 11.0 (1.8) 1.4 (2.4) < .001
Mean Number of Reads (SD) 3893 (783) 3760 (1038) n.s. N/A N/A N/A N/A
Total Number of Reads 73969 289492 N/A N/A N/A N/A
➔Assigned at Phylum 73876
(99.9%)
289117
(99.9%)
n.s. N/A N/A N/A N/A
➔Assigned at Genus 61657
(83.4%)
230370
(79.6%)
n.s. N/A N/A N/A N/A
Mean Number of OTU (SD) 389 (103) 429 (157) n.s. N/A N/A N/A N/A
Total Number of OTU 7041 33048 N/A N/A N/A N/A
Mean Shannon index f 5.3 5.2 n.s. N/A N/A N/A N/A
Mean Chao index f 604.5 579.7 n.s. N/A N/A N/A N/A
a Four sibling pairs were included in the ADHD group, ten sibling pairs and two trio’s in the control group. Four ADHD cases had one sibling in the control
group. No BMI was available for four control subjects.
b Four sibling pairs were included in the ADHD group, 13 sibling pairs and six trio’s in the control group. Nine ADHD cases had one sibling in the control
group; one ADHD case had two siblings in the control group. No BMI was available for two ADHD and three control subjects. Initially, 95 participants
performed the reward anticipation task during fMRI. However, four ADHD participants and four control participants were excluded from the fMRI analyses:
five were excluded due to excessive (i.e. > 6 mm) movement (three ADHD + two controls), one due to an incomplete data set (ADHD), one due to too many
errors (48%, control), and one due to extensive signal drop-out (control).
c One sibling pair was included in the ADHD group, eight sibling pairs in the control group. One ADHD case had one sibling in the control group. No BMI was
available for two control subjects.
d Differences in gender between the groups were tested with chi-square or Fisher’s exact test, as appropriate. All other differences were tested with an
independent t-test.
e No symptoms were available for n = 39 control subjects.
f Metrics for alpha diversity; reads were down-sampled to 1126 reads per sample, average of 4 trials, for the calculation of this diversity metric.
N/A: Not Available; BMI: Body Mass Index; OTU: Operational Taxonomic Unit; SD: Standard Deviation; n.s.: not significant.
https://doi.org/10.1371/journal.pone.0183509.t001
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Statistical inference (p< 0.05) was performed at the cluster level, correcting for multiple com-
parisons (Family Wise Error, FWE) over the search volume, i.e. the whole brain.
We investigated the effects of diagnosis using a ventral striatum region of interest (ROI),
i.e. an anatomically-defined bilateral nucleus accumbens region (Text B in S1 Appendix).
Microbiome analysis
Microbial faecal DNA extraction. Feacal samples were collected using a standard method
consisting in scooping a pea-sized piece of feces and storing it in a 50ml Falcon tube. The sam-
ple was then stored at 4˚C straight after collection and at -80˚C within 24 hours. Faecal geno-
mic DNA from self-collected stool samples was isolated using the DNeasy1 Blood and Tissue
Kit (Qiagen, Venlo, The Netherlands) as described earlier [26]. The DNA was treated with
RNase and eluted in Qiagen elution buffer AE. DNA purity and quantity were checked by
spectrophotometry (ND-1000, NanoDrop Technologies, Wilmington, DE, USA).
16S marker gene amplification, sequencing and data acquisition. Preparation of the
amplicon pool for pyrosequencing followed established protocols [27], and is described in
detail in Text C in S1 Appendix, where additionally sequencing and data acquisition is out-
lined. In short, hypervariable V3-V4 region of the 16S rRNA gene was sequenced on the 454
Life Sciences GS-FLX platform using Titanium sequencing chemistry (GATC-Biotech,
Germany).
Microbiome sequencing data analysis. For gene sequencing analysis, a customized
Python workflow based on Quantitative Insights Into Microbial Ecology (QIIME version 1.2)
was adopted (http://qiime.org) [28] (Text C in S1 Appendix).
Microbiome-derived function prediction. Based on the generated 16S profiles of the gut
microbiome for ADHD and control subjects for the full microbiome cohort, we predicted the
presence of Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthologs and subsequent
functional and metabolic pathways using PICRUSt (Text C in S1 Appendix). Based on the
KEGG (http://www.genome.jp/kegg/) pathway maps of ‘Phenylalanine, tyrosine and trypto-
phan biosynthesis’ (ko00400, ko00360, ko00350 and ko00380), the 17 candidate reactions/
enzymes that directly result in production of phenylalanine, tyrosine, or tryptophan were
selected: EC:1.3.1.43; EC:1.3.1.78; EC:1.3.1.79; EC:1.4.1.20; EC:1.4.3.2; EC:1.14.16.1; EC:2.6.1.1;
EC:2.6.1.5; EC:2.6.1.57; EC:2.6.1.58; EC:2.6.1.9; EC:4.1.99.1; EC:4.1.99.2; EC:4.2.1.20; EC:4.2.1.51;
EC:4.2.1.91 and EC:5.1.1.11 [29] (Fig B in S1 Appendix). From the relative abundances of gene
functions predicted by PICRUSt we focused on candidate reactions/enzymes, by applying in-
house bioinformatic (Perl-coded) scripts. Relative abundances of reactions/enzymes were cal-
culated (Text C in S1 Appendix) for each individual sample based on all observed KEGG
Orthologs, for each hierarchical functional KEGG level. To determine the contribution of the
candidate microbial taxa, i.e. those (marginally) differing between ADHD and controls, to differ-
ences observed in the selected monoamine precursors, the PICRUSt analysis was repeated on
the subset of candidate taxa only to find the taxa responsible for the observed functional effects.
Microbiome data analysis and statistics. Statistics on the relative abundances of selected
monoamine biosynthetic pathways (K numbers: KEGG orthology groups) or taxa between
sample groups was performed with SciPy (http://www.scipy.org) using a non-parametric
Mann–Whitney U (MWU) test with Bonferroni correction for (i) multiple comparisons across
all microbial taxa in all levels of phylogenetic classification (in analyses of phylogenetic compo-
sition), or (ii) across all pathways of the same KEGG hierarchical pathway level (in analyses of
predicted functionality), unless stated otherwise. Relative abundance of taxa was correlated
with relative abundance of enzymes/reactions (i.e. K numbers) using Spearman correlation.
Subsequently, we repeated this analysis with multiple regression (in SPSS, see above) to assess
Gut microbiome in ADHD
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the unique contribution of taxa to the predicted reaction of interest, using the 16S-based taxa
as predictors and the enzymes/reactions predicted to be present in those taxa (by PICRUSt), as
dependent variables. For any additional downstream sequencing-related data analysis, figures,
and statistics, Microsoft1 Office Excel1 2007 and GraphPad Prism version 5.03 were used.
Data availability. The raw, unprocessed 16S 454-sequencing reads are publicly available
for download at the European Nucleotide Archive (ENA) database (http://www.ebi.ac.uk/ena)
under study accession number PRJEB11512 (or secondary accession number ERP012909)
[30]. The sequencing data is available in fastq-format, including corresponding metadata for
each sample.
Effects of microbiome on reward anticipation (fMRI)
In final analyses, we tested how microbiome function related to brain function. Across the
whole sub-sample with both microbiome and fMRI measures available (n = 28), we assessed
the effects of relative abundance of a candidate predicted microbiome-derived enzyme/reac-
tion as covariate of interest on whole-brain reward anticipation responses (in SPM) with the
reward anticipation (high > low) images (pFWE < 0.05, cluster-level, small volume: bilateral
nucleus accumbens region from the Hammersmith atlas (Text B in S1 Appendix).
We also performed multiple linear regression with the ventral striatum ROI betas for reward
anticipation (see above) as dependent variable and the microbiome measure as well as ADHD
diagnosis, age, gender, and stimulant medication use as predictors (Text B in S1 Appendix).
Results
Demographics
The ADHD cases and healthy participants did not differ in BMI and gender in the three
groups (microbiome, fMRI, and their overlap) (Table 1). No differences in age were present
for patients and healthy persons in the fMRI samples, but for the microbiome analyses, con-
trols were older (Table 1). This was due to the fact that the 39 BIG participants were older
(33.1 years ± 17.7 SD). Controls from the NeuroIMAGE II study (21 unaffected siblings [22.3
years ± 3.7 SD], and 17 healthy controls [19.1 years ± 3.2 SD]) did not differ from the cases (t
(55) = -1.46, p = .15). Consequently, the functional (PICRUSt) analyses below were performed
with and without the older BIG controls to balance power and homogeneity of the sample.
Gut microbiome taxa
For sample characteristics, diversity metrics and read counts, see S1 Table and Text D in S1
Appendix. The overall make-up of the 96 microbiomes consisted of bacteria predominantly
from the phyla Firmicutes (77.92%), Actinobacteria (15.68%) and Bacteroidetes (6.05%) (Fig
3; Fig C in S1 Appendix; S2 Table). We found an increase of Actinobacteria (controls: 14.08%
to ADHD: 22.14%; p = 0.002, uncorrected), which seemed to occur mainly at the expense of
Firmicutes (controls: 79.80% and ADHD: 70.29%; p = 0.001, uncorrected), as Bacteroidetes
(and other phyla) did not differ significantly (controls: 5.74% to ADHD: 7.29%; p = 0.166,
uncorrected) in relative abundance between healthy participants and those with ADHD (S2
Table; MWU, multiple comparisons corrected p-value threshold = 0.00017). Interestingly, in
more taxonomic detail, within the phylum Actinobacteria, the genus Bifidobacterium was sig-
nificantly increased in ADHD cases (controls: 12.66% to ADHD: 20.47%; p = 0.002, MWU,
uncorrected) (Fig 3). Bifidobacterium dominates the gut early in life, and slowly decreases in
relative abundance during ageing [31]. In order to exclude an age-driven shift in Bifidobacter-
ium, we defined an age-matched subsample for our microbiome cohort (Text D in S1
Gut microbiome in ADHD
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Appendix). Using 15 pairs of ADHD cases and age-matched controls we find a similar rise in
Bifidobacterium in ADHD-affected individuals (controls: 13.77% to ADHD: 18.90%) (p =
0.034, MWU, uncorrected). Furthermore, the order Clostridiales, within the phylum Firmi-
cutes, was found to be decreased in ADHD cases (controls: 77.37% to ADHD: 69.02%;
p = 0.003, MWU, uncorrected) and best explains the observed drop in Firmicutes, but no spe-
cific taxonomical entity belonging to the order Clostridiales was found to be responsible for
this effect (Fig 3). In conclusion, the genus Bifidobacterium shows the most (statistically)
strong and taxonomic most specific change as effect of ADHD status.
We selected five candidate taxa with the greatest difference between ADHD and controls to
be used in our subsequent analyses of metabolic potential (by PICRUSt): Clostridiales (order),
Rikenellaceae (family), Porphyromonadaceae (family), Bifidobacterium (genus) and Eggerthella
(genus).
Hypothesis-driven analysis of gut microbiome metabolic potential
We predicted bacterial gene function using PICRUSt, focusing on pathways involved in the
synthesis of phenylalanine, tyrosine, and tryptophan, which can serve as precursors of human
dopamine, noradrenaline and serotonin (Fig 1).
Relative abundances of the 17 candidate reactions/enzymes (pathways) that are directly
involved in the production of phenylalanine, tyrosine, or tryptophan (Fig B in S1 Appendix)
were predicted based on the total gut microbiome of healthy controls and ADHD cases. For
these 17 a priori selected candidates, 15 K numbers could be identified in the microbiome (S3
Table). One predicted enzyme, cyclohexadienyl dehydratase (CDT; KEGG Ortholog K01713;
EC:4.2.1.51), was found to be significantly more abundant (on average, 150% more than in
controls) in the microbiome of ADHD cases (p = 0.038 by MWU, Bonferroni-corrected for 15
K numbers identified) (Fig 4; S3 Table). Moreover, CDT ranked among the top ~1% of a total
of 7545 reactions (when we sort our reaction p-values from low to high (S3 Table). Similar
results of ADHD cases versus controls were obtained with the sample groups matched for age
(i.e. without the older BIG controls), though significance is lost (p = 0.085, Bonferroni-cor-
rected). Using logistic regression to control for age (and gender; Text D in S1 Appendix) the
results in the age-matched sample (i.e. without the BIG controls) hint to the fact that the
change in ADHD for K01713 is a significant effect (p = 0.024), but the marginal effect in the
complete sample (p = 0.070) shows that our results cannot be completely disconnected from
the age confounder present in the cohorts studied (Text D in S1 Appendix).
To assess which of the five taxa differing between cases and controls (Fig 3) contributed
most to the observed difference in the predicted enzyme CDT, we repeated the functional
(PICRUSt) analysis for these candidate taxa only: Clostridiales (order), Rikenellaceae (family),
Porphyromonadaceae (family), Bifidobacterium (genus) and Eggerthella (genus) (Fig 3). Dif-
ferences in relative abundance of the genus Bifidobacterium uniquely contributed to the
observed differences in the predicted phenylalanine pathway enzyme CDT in a multiple
regression analysis (p< 0.001). The same conclusion was drawn from the fact that in the
cohort Bifidobacterium contributed 99.9% of the predicted CDT (K01713) counts relative to
Fig 3. The strongest differentially abundant microbial taxa for ADHD cases (n = 19) versus healthy controls (n = 77), shown in the
graphical Cytoscape visualization [32]. Nodes represent taxa (node size represents average relative abundance, for both experimental
groups combined), edges (dashed lines) link the different taxonomic levels. The weighed fold-change (node color) is calculated as the 2log
of the ratio of the relative abundance between control and ADHD (0 = no difference between genotypes, 1 = twice as abundant in control,
etcetera). In other words: yellow to red indicates an overrepresentation in control, hence an underrepresentation in ADHD, and vice versa for
light- to dark blue. The significance (node border width) is expressed as the p-value of a Mann–Whitney U test, uncorrected for multiple
comparisons.
https://doi.org/10.1371/journal.pone.0183509.g003
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the predicted CDT counts based on PICRUSt analysis of the entire microbiome (n = 16,340;
Text D in S1 Appendix).
fMRI: Effects of reward anticipation and diagnosis
In a partly overlapping sample of the same cohort, we tried to replicate reduced reward antici-
pation in ADHD versus controls (see Introduction). Across the whole sample, reward anticipa-
tion (high (15 ct)> low (1 ct) cues) elicited brain responses in the striatum and the occipital,
premotor, and frontal cortices (pFWE < 0.05, whole-brain, cluster-level correction) in our
total fMRI sample (n = 87) as well as the sub-sample with microbiome data (n = 28) (Fig 5A;
Text E in S1 Appendix). Taking the anatomically-defined ventral striatal ROI, we indeed
found decreased ventral striatal responses for reward anticipation in patients with ADHD ver-
sus controls (t(85) = 2.1, p = 0.038) (Fig 5B). This difference was not significant in the sub-
sample with microbiome data (t(26) = 0.2).
fMRI: Effects of the microbiome on reward anticipation
Finally, we assessed how the functional microbiome measure found to be different for ADHD
relative to controls (i.e. predicted CDT), would relate to neural reward anticipation in the sub-
sample with both microbiome and fMRI data. Across the whole sub-sample (n = 28), indepen-
dent of diagnosis, we observed a negative association (whole-brain) of the relative abundance
of predicted CDT with reward anticipation responses in bilateral ventral striatum (Fig 5C).
This effect was also significant in the ventral striatal ROI analysis (standardized beta: -0.48,
p = 0.032), when including possible confounding factors (ADHD diagnosis, age, and gender)
in the analysis. Also, when adding stimulant use (duration times dose) to control for long-
term medication effects, predicted CDT relative abundance was still significantly associated
with reward anticipation responses in ventral striatum (standardized beta: -0.42, p = 0.048).
Fig 4. The ADHD microbiome contains significantly increased levels of predicted cyclohexadienyl
dehydratase (CDT; KEGG Ortholog K01713; EC:4.2.1.51), responsible for phenylalanine synthesis
(Fig B in S1 Appendix). This analysis is based on functional predictions deriving from 16S profiles of the
microbiome, as performed by PICRUSt [33]. Box plots represent the relative abundance of predicted CDT,
with 5–95% percentile whiskers (dots represent outliers). The significance was tested with a non-parametric
MWU (* p = 0.038), Bonferroni-corrected for 15 K numbers identified.
https://doi.org/10.1371/journal.pone.0183509.g004
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Fig 5. fMRI results. A. Main effect of reward anticipation, cluster-level corrected at the whole-brain level
(pFWE < 0.05). Color bars reflect T-values. B. Diagnosis effects in the anatomical region of interest (ROI) of
the ventral striatum. C. Negative correlation of the microbiome function CDT (see Fig 4) with reward
anticipation responses across the whole-brain (n = 28), intensity threshold at p < 0.001 uncorrected (T = 3.45).
The clusters in bilateral ventral striatum (x = -11, y = 11, z = -9, cluster size = 8, p(FWE, cluster) = 0.024;
x = 11, y = 6, z = -11, cluster size = 2, p(FWE, cluster) = 0.036) are significant after correcting for multiple
comparisons across the search volume (cluster-level pFWE < 0.05, SVC), i.e. the anatomically defined
ventral striatum shown in panel B. SVC = small volume correction. * indicates p < 0.05.
https://doi.org/10.1371/journal.pone.0183509.g005
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Discussion
This is the first study investigating microbiome differences between ADHD cases and controls.
Observed differences in taxa in this exploratory study were strongest for the phylum Actino-
bacteria, which was more abundant in cases, apparently at the expense of Firmicutes, for
which abundance was lower in cases; uncorrected for multiple comparisons. In addition, we
describe for the first time effects of a genetically encoded capacity for production of mono-
amine precursors in the gut microbiome of ADHD: the enzyme CDT, involved in the synthesis
of a dopamine precursor (phenylalanine), was predicted to be significantly more abundant in
the microbiome of ADHD cases compared to healthy individuals (corrected for multiple com-
parisons). This effect appeared dependent on age, although significant effects were obtained
with age-matched samples. The genus Bifidobacterium (within the phylum Actinobacteria)–
also more abundant in (age-matched) ADHD versus controls (uncorrected for multiple com-
parisons)–appeared to be solely responsible for this predicted enzyme CDT increase. Across
the sample (i.e. independent of diagnosis), the abundance of predicted CDT genes from the
microbiome correlated negatively with bilateral ventral striatal BOLD responses for reward
anticipation (corrected for multiple comparisons in an anatomically-defined search volume),
typically reduced in ADHD [4–7] and replicated here.
Pa¨rtty and colleagues [19] recently used markers for specific bacterial species to show that
decreased numbers of Bifidobacterium (e.g. Bifidobacterium longum) in 3 and 6 months old
children (treated with either a Lactobacillus-based probiotic or a placebo) predicted ADHD
or Asperger syndrome manifestation at age 13 years [19]. At the time of diagnosis (13 years
old), they did not observe any significant difference in the assessed taxa, including Bifidobac-
terium, between ADHD and controls. This difference with our marginally significant result of
increases in Bifidobacterium in ADHD might be explained by (i) our more sensitive method
(16S marker gene sequencing versus PCR), and (ii) larger sample size (19 ADHD and 77 con-
trols versus 6 ADHD/Asperger and 69 controls) or (iii) differences introduced by experimental
procedures or between cohorts. The observed differences in Bifidobacterium genus between
controls and adolescents/adults with ADHD (current study) or infants developing ADHD
later in life [19]–in opposite direction–require formal replication in longitudinal studies with
larger samples. Decreased abundance of Bifidobacterium in early infancy versus increased
abundance in early adulthood might reflect delayed gut microbiome maturation in ADHD, as
Bifidobacterium is known to decline with older age [31]. Pa¨rtty and colleagues [19] found that
Bifidobacterium in infancy predicted ADHD and Asperger syndrome. Changes in microbiome
composition have indeed consistently been found in autism spectrum disorder [34]. Although
participants with DSM-IV defined Autistic Disorder and other neuropsychiatric disorders
were excluded, we cannot be certain that the current findings are specific for ADHD.
Bifidobacterium was responsible for increases in the predicted function of CDT (K01713)—
involved in the synthesis of phenylalanine (Fig B in S1 Appendix)—in ADHD cases versus
controls. Phenylalanine is an essential amino acid, which cannot be synthesized by humans
and has to be absorbed from the gut[21]. Phenylalanine can cross the blood-brain barrier and
is the precursor of dopamine and noradrenaline [20] (Fig 1). These neurotransmitters are
highly affected in ADHD, nevertheless, the exact mechanisms of involvement are still ambigu-
ous [35–37]. Predicted CDT correlated negatively with ventral striatal responses during reward
anticipation. Striatal reward anticipation responses are modulated by dopamine and remedi-
ated by methylphenidate [3, 38]. Our findings suggest that gut microbial-induced levels of
CDT correlate functionally with available levels of the dopamine precursor phenylalanine,
which could potentially be a risk factor for disturbed dopamine signaling and reduced brain
reward responses. Indeed, high levels of phenylalanine have been linked to ADHD symptoms
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[39]. However, this association was found in phenylketonuria, a disorder in which phenylala-
nine cannot be converted to tyrosine, which results in toxic build-up of phenylalanine in the
brain. Two other studies, using an overlapping sample, have found decreased blood plasma
concentrations of phenylalanine in ADHD [40, 41] and a more recent and larger study did not
observe an association between peripheral (i.e. blood and urine) levels of phenylalanine and
ADHD [42]. Future studies should link the presently observed increases in predicted micro-
biome-derived phenylalanine to peripheral levels of phenylalanine and study how this relates
to brain function.
Moreover, the mechanism by which the increased predicted CDT function (and specula-
tively, increased phenylalanine) would result in decreased striatal BOLD responses for reward
anticipation remains to be investigated. Many different routes for a potential causal relationship
are possible. Microbial phenylalanine could be absorbed in the blood stream, cross the blood-
brain barrier, and influence dopamine synthesis (Fig 1) positively or negatively (by inhibiting
tyrosine hydroxylase) [43]. Alternatively, on the host side, altered blood plasma levels of phenyl-
alanine (or its derivate tyrosine) could have an effect on the synthesis of neuromodulators other
than dopamine, e.g. by competing at the blood-brain barrier with tryptophan (precursor of
serotonin) or by conversion to trace amines [20, 44, 45]. In addition, yet unknown interactions
of multiple bacterial groups involved in the production of neuroactive substances might affect
host neurophysiology within the gastrointestinal tract [15]. Nevertheless, our observed relation-
ship between the microbial phenylalanine pathway and neural responses for reward anticipa-
tion, known to depend on phenylalanine’s derivate dopamine, may argue for a dopaminergic
effect at the level of the brain instead of the gut. Future research should confirm this and show
specificity for microbial functions, as well as brain regions and associated functions.
Our study should be viewed in the context of its strengths and limitations. Obvious
strengths include the 16S microbiome analysis (instead of preselected candidate taxa), larger
sample size than previous studies in ADHD [19], and our mechanistic, hypothesis-driven
approach in terms of predicted enzymes (function analysis) as well as their link to brain func-
tioning using fMRI. As for limitations, a microbiome shotgun sequencing method preferably
combined with a proteomics or metabolomics approach instead of the 16S marker gene
method might have allowed us to make more solid claims about microbial biological function.
Second, about 25% of our control participants were siblings of ADHD cases (see Table 1), and
another sub-sample of the control group did not undergo clinical screening for ADHD (the
BIG sample). However, in both cases this would be more likely to cause an underestimation of
differences between ADHD cases and controls. Third, the control group was significantly
older than the ADHD cases. Consequently, the age confounder in our study hampered us
from attributing the significant change in predicted CDT exclusively to ADHD. Nevertheless,
our study suggests that the change in ADHD for the CDT enzyme (K01713) is a significant
effect, with subject age having an important contribution. This might in part be explained by
the explicit nature of ADHD for which it is recognized that its prevalence diminishes with age
[46]. Importantly, the gut-microbiome-brain association between predicted CDT and reward
anticipation fMRI responses was observed independent of age. Fourth, it is well known that
diet affects microbiome structure/stability [13]. In this respect, having a substantial part of the
control group consisting of unaffected siblings of ADHD cases (21/77), presumably living in
the same household with similar diets, should be viewed as a strength of this study. Impor-
tantly, we did not observe any differences in body mass index between the groups. Fifth, our
gut-microbiome-brain association was found independent of, or actually controlled for,
ADHD diagnosis. Hence, we can only conclude that functional differences found between
ADHD and controls at the microbiome level are related to neural effects across subjects.
ADHD status-specific conclusions about this gut-brain relation might be made in future
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studies with larger group sizes. Finally, given the generally observed beneficial effects of Bifido-
bacterium [47, 48], it remains to be resolved in subsequent studies whether our observed effects
are a consequence or, perhaps, a compensatory, effect of ADHD status. Considering these
uncertainties, our novel functional gut-brain approach provides many leads for new research,
but caution should be taken to translate these findings to non-pharmacological intervention
strategies in ADHD.
Conclusions
This is the first study demonstrating differences in the gut microbiome between patients with
ADHD and healthy individuals, using a comprehensive 16S microbiome analysis, and show-
ing–if anything–an increase in the genus Bifidobacterium. This increase was associated with
significantly enhanced predicted biosynthesis potential of a dopamine precursor in the gut
microbiome of ADHD patients versus controls, which was linked to altered reward anticipa-
tion responses in the brain, a neural hallmark of ADHD. With this mechanistic approach, we
hypothesize that presumed differences in dopamine precursor production at the gut micro-
biome level in ADHD might be related to dopamine disturbances at the neural level associated
with reduced brain reward responses. This study highlights the importance of investigating the
functional effects of microbiome differences in neuropsychiatric disorders.
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